Comparative Pharmacology
Head-to-head clinical analysis: CISPLATIN versus ZEPZELCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CISPLATIN versus ZEPZELCA.
CISPLATIN vs ZEPZELCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Platinum-based alkylating-like agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Lurbinectedin is a selective inhibitor of oncogenic transcription. It binds to the minor groove of DNA, inhibiting the activity of RNA polymerase II and promoting its degradation, thereby reducing transcription of certain oncogenes and inducing apoptosis in cancer cells.
50-100 mg/m² IV every 3-4 weeks; or 20 mg/m² IV daily for 5 days every 3-4 weeks.
3.24 mg/m2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateCisplatin + Digoxin
"Cisplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCisplatin + Digitoxin
"Cisplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCisplatin + Deslanoside
"Cisplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCisplatin + Acetyldigitoxin
"Cisplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is 20-30 hours (range 10-40 hours) in patients with normal renal function. This prolonged half-life is due to slow release of platinum from tissue binding and is clinically relevant for cumulative nephrotoxicity and ototoxicity.
Terminal elimination half-life is approximately 7-9 hours in patients with normal hepatic function, supporting once-daily dosing.
Renal excretion accounts for 70-90% of cisplatin elimination, with approximately 20-50% excreted unchanged in the urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Primarily hepatic metabolism, with biliary/fecal excretion as the major route (approximately 60-80% of the administered dose). Renal excretion accounts for <20% of the dose as unchanged drug and metabolites.
Category D/X
Category C
Alkylating Agent
Alkylating Agent